Persistent reduction of mitral regurgitation by implantation of a transannular mitral bridge: durability and effectiveness of the repair at 2 years—results of a prospective trial†

Černý, Štěpán; Benešová, Miroslava; Skalský, Ivo; Patel, Nirav; Subramanian, Valavanur A.

doi:10.1093/ejcts/ezy423

Cited by 8 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 2 years, no strokes or device-related adverse events were noted, and the MR was reduced from 3.32 ± 0.47 to 0.50 ± 0.83 ( P < 0.001), with <1+ MR in 33/34 patients (including four reinterventions for periprosthetic recurrent MR ≥3 without mitral bridge explants or conventional mitral repair or replacement). At 2 years, the mean mitral gradient was 2.15 ± 0.82 mmHg, and the mitral annular septo-lateral dimension decreased from 40.4 ± 2.91 to 28.9 ± 1.55 mm (36).…”

Section: Emerging Devicesmentioning

confidence: 98%

Emerging Technologies for Percutaneous Mitral Valve Repair

Mangieri

Laricchia

Giannini

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Mitral regurgitation (MR) is a common disease affecting more than 4 million people in the United States and the European Union. A significant number of percutaneous valves have been developed recently, specifically designed for the mitral anatomy, and with a promising evidence of good procedural and echocardiographic outcomes. However, even if transcatheter mitral valve replacement (TMVR) will have a role in the future of percutaneous treatment of both functional and degenerative mitral regurgitation, percutaneous mitral valve repair will always play a vital role in the treatment of MR because of the favorable safety profile and the fact that it respects the native anatomy. In this review, we will discuss the new emerging technologies under development to treat mitral regurgitation focusing on different devices that aim to target different components of the mitral anatomy.

show abstract

Section: Emerging Devicesmentioning

confidence: 98%

Emerging Technologies for Percutaneous Mitral Valve Repair

Mangieri

Laricchia

Giannini

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…It now is the gold standard against which any new device will be compared. Several new percutaneous repair or replacement techniques (36)(37)(38)(39)(40)(41)(42)(43) are the subject of a dedicated keynote lecture and will not be discussed herein, but will be discussed in detail in another chapter of this issue.…”

Section: Secondary Mr In Non-icm (N-icm)mentioning

confidence: 99%

The unfinished saga of invasive procedures for secondary mitral regurgitation

Grinberg

Uhlrich

Thivolet

et al. 2021

Ann Cardiothorac Surg

View full text Add to dashboard Cite

Secondary mitral regurgitation (MR) is a common valvular heart disease. Its prognostic burden in patients suffering from idiopathic or ischemic cardiomyopathy (ICM) with left ventricular (LV) dysfunction/dilation has been clearly demonstrated. Severe secondary MR is associated with an increased mortality and frequent heart failure hospitalizations. Although guideline-directed medical therapy (GDMT) is the cornerstone of the management of secondary MR, a certain proportion of patients remain symptomatic. For these patients, several surgical techniques have been progressively developed during the last few decades (replacement, repair, sub-valvular apparatus interventions and other ventricular approaches). In the absence of evidencebased medicine, the benefits of these surgical procedures remains controversial, leading to a low level of recommendation in the guidelines. One way to anticipate the future is to look to the past. Recent prospective randomized trials evaluated surgical and percutaneous techniques and led to a better understanding of how best to treat this disease. In this article, we aim to describe the saga of the surgical and percutaneous treatments for secondary MR throughout the previous decades.

show abstract